Literature DB >> 173750

An action of disodium cromoglycate: inhibition of cyclic 3',5'-AMP phosphodiesterase.

N Lavin, G S Rachelefsky, S A Kaplan.   

Abstract

Disodium cromoglycate (DSCG) prevents allergic asthma by inhibiting the release of chemical mediators of immediate-type allergic reactions. The mechanism of this action is unclear and prompted us to examine the effect of DSCG on cyclic adenosine 3',5'-monophosphate (cAMP), the implicated regulator of IgE-mediated reactions. We used the peripheral blood lymphocyte as a model to mirror the biochemical events occurring in the allergic shock organs. Isolated peripheral blood lymphocytes from perennial allergic asthmatic children receiving only DSCG had significantly (p less than 0.005) lower phosphodiesterase (PDE) activity (mean 1.05 +/- 0.17 SE per 10(6) cells) than normal individuals (2.93 +/- 0.14) and allergic children receiving methylxanthines (4.08 +/- 0.28) or no medications (3.58 +/- 0.2). DSCG (10 mug/ml) significantly lowered PDE activity in normal lymphocytes (p less than 0.005) in a beef heart extract (p less than 0.001), and 100 mug/ml lowered PDE activity in fetal rabbit lung homogenates (p less than 0.001). DSCG (10 mug/ml) significantly elevated (p less than 0.01) cAMP concentration in normal human lymphocytes (118 +/- 38 vs 30 +/- 10 picomoles cAMP/10(6) lymphocytes). Thus, DSCG appears to inhibit chemical mediator release by increasing intracellular cAMP through the inhibition of cAMP PDE.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 173750     DOI: 10.1016/0091-6749(76)90081-6

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  13 in total

1.  Protective effect of drugs on histamine-induced asthma.

Authors:  D W Cockcroft; D N Killian; J J Mellon; F E Hargreave
Journal:  Thorax       Date:  1977-08       Impact factor: 9.139

2.  Effects of [N-(2-oxo-3,5,7-cycloheptatrien-1-yl)] aminooxoacetic acid ethyl ester (AY-25,674) on cyclic 3',5'-nucleotide formation and phosphodiesterase activity.

Authors:  T A Pugsley; W Lippmann
Journal:  Experientia       Date:  1979-01-15

Review 3.  Ocular sodium cromoglycate. An overview of its therapeutic efficacy in allergic eye disease.

Authors:  E M Sorkin; A Ward
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

Review 4.  Cromolyn.

Authors:  B A Berman; R N Ross
Journal:  Clin Rev Allergy       Date:  1983-03

5.  Eosinophil degranulation. Monitoring by interference contrast microscopy.

Authors:  R Sher; A A Wadee
Journal:  Inflammation       Date:  1981-03       Impact factor: 4.092

Review 6.  Mechanisms of exercise-induced asthma.

Authors:  E Bar-Yishay; S Godfrey
Journal:  Lung       Date:  1984       Impact factor: 2.584

Review 7.  Pharmacologic treatment of rhinitis.

Authors:  F E Simons; K J Simons
Journal:  Clin Rev Allergy       Date:  1984-08

8.  Inhibition of aspirin-induced bronchoconstriction by sodium cromoglycate inhalation.

Authors:  N A Martelli; G Usandivaras
Journal:  Thorax       Date:  1977-12       Impact factor: 9.139

Review 9.  Drug treatment of allergic conjunctivitis. A review of the evidence.

Authors:  G Ciprandi; S Buscaglia; P M Cerqueti; G W Canonica
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

10.  Mechanisms of the bronchoconstrictor effects of deep inspiration in asthmatic patients.

Authors:  P Gayrard; J Orehek; C Grimaud; J Charpin
Journal:  Thorax       Date:  1979-04       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.